Suppr超能文献

一期凝血酶原时间在抗凝治疗控制中的“治疗范围”:不同凝血活酶制剂的影响

The "therapeutic range" of the one-stage prothrombin time in the control of anticoagulant therapy: the effect of different thromboplastin preparations.

作者信息

Bailey E L, Harper T A, Pinkerton P H

出版信息

Can Med Assoc J. 1971 Nov 20;105(10):1041-3 passim.

Abstract

Commercially available thromboplastin reagents and two human brain preparations have been compared using the one-stage prothrombin time and plasma samples from patients receiving long-term oral anticoagulant therapy. Considerable variation is noted between various thromboplastins using the same plasma sample. The commercially available thromboplastins give shorter prothrombin times than do human brain preparations. With the latter, the "therapeutic range" is represented by a prothrombin time of about 1.8 to 3.0 times the normal control value, whereas with commercial preparations the "therapeutic range" is about 1.25 to 1.75 times normal. The implications of these observations are discussed; the desirability of standardization of the one-stage prothrombin time is emphasized.

摘要

使用一期凝血酶原时间以及接受长期口服抗凝治疗患者的血浆样本,对市售凝血活酶试剂和两种人脑制剂进行了比较。使用相同血浆样本时,发现不同凝血活酶之间存在显著差异。市售凝血活酶的凝血酶原时间比人脑制剂的短。对于人脑制剂,“治疗范围”由凝血酶原时间约为正常对照值的1.8至3.0倍表示,而对于市售制剂,“治疗范围”约为正常对照值的1.25至1.75倍。讨论了这些观察结果的意义;强调了一期凝血酶原时间标准化的必要性。

相似文献

4
[Prothrombin time and its standardization].
Rinsho Byori. 2002 Aug;50(8):779-85.
5
Standardization of coagulation tests.
Southeast Asian J Trop Med Public Health. 1999;30 Suppl 3:79-85.
10
[Prevention of venous thromboses with oral anticoagulants].
Wien Med Wochenschr. 1989 Dec 15;139(23):559-62.

引用本文的文献

2
Risk of haemorrhage associated with long term anticoagulant therapy.
Drugs. 1985 Nov;30(5):444-60. doi: 10.2165/00003495-198530050-00004.

本文引用的文献

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验